Scientific Knowledge
Acousia Therapeutics GmbH
Company
Privately held clinical-stage biotechnology company based in Tübingen, Germany. Developer of bimokalner (ACOU085), a Kv7.4 potassium channel opener; reported positive Phase 2a PROHEAR study results in 2026 for prevention of cisplatin-induced hearing loss.
Explore connections· click any item to explore
Treatments1